HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Dalgleish, A G Search for Related Content PubMed PubMed Citation Articles by Dalgleish, A G

Current problems in the development of specific immunotherapeutic approaches to cancer

Department of Oncology, Gastroenterology, Endocrinology and Metabolism, Division of Oncology, St George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK

Over the past decade there has been a widespread resurgence of interest in the concept of cancer immunotherapy and the design of new cancer vaccines. The discovery of tumour specific and tumour associated antigens has resulted in a large number of targets that are currently being developed as potential clinical products. These are comprehensively reviewed by Jäger et al.¹

Although the identification of tumour antigen epitopes by cytotoxic T lymphocytes (CTL) is certainly an elegant and logical approach, there is a disturbing lack of correlation between CTL activity to these epitopes and clinical response.² Moreover, it seems that there is a distinctive lack of help for a second signal in many reductionistic approaches because responses are often seen only after the addition of interleukin 2 (IL-2).³

In addition to specific immune responses, it may be that an appropriate innate immune response is as important or more important for cancer . . . [Full text of this article]